MarketCapExport financials
Adaptive Biotechnologies Corporation (ADPT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Adaptive Biotechnologies Corporation Income Statement 2025-2011 | ADPT
Brief overview of financial results at Adaptive Biotechnologies Corporation
The comparison covers a five-year financial horizon. According to figures from Adaptive Biotechnologies Corporation, revenue changed from $98.4 million to $277 million over five years. Across the full period, sales moved by +181.5%; the average annual rate was 23%. Sales grew at a rate typical of a strong expansion phase.
The five-year change in gross profit reached +171.1%: from $75.9 million to $206 million. Costs absorbed a larger share of revenue over the period. Gross profit as a share of revenue changed from 77.1% to 74.2%. The margin decline reflects a less favorable sales-and-cost structure.
The five-year EBITDA result moved by +71.8%: from −$146 million to −$41.1 million. Changes in revenue did not translate into comparable EBITDA performance. At the operating-margin level, the figure shifted from −148.4% to −14.8%. The increased EBITDA share is a positive sign.
Across the five years, the net result shifted from −146 million dollars to −59.5 million dollars. The loss reduction is constructive, but the recovery is incomplete.
The five-year change in capitalization reached −66.6%: from $7.4 billion to $2.5 billion. The market is not yet fully reflecting the fundamental progress.
Summary assessment
Signs of deterioration dominate the five-year picture. The positive side is supported by a larger revenue base, net-income growth and positive operating leverage. The weaker side of the profile includes a lower gross margin, lower investor confidence and a narrow EBITDA buffer. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Adaptive Biotechnologies Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.48 B | 1.18 B | 596 M | 1.23 B | 2.03 B | 7.42 B | 2.13 B | - | - | - | - | - | - | - | - |
Shares |
152 M | 147 M | 144 M | 143 M | 140 M | 131 M | 69.2 M | - | - | - | - | - | - | - | - |
Historical Prices |
16.4 | 8.01 | 4.13 | 8.61 | 14.4 | 56.6 | 28.1 | - | - | - | - | - | - | - | - |
Net Income |
-59.5 M | -159 M | -225 M | -200 M | -207 M | -146 M | -68.6 M | -46.4 M | -42.8 M | - | - | - | - | - | - |
Revenue |
277 M | 179 M | 170 M | 185 M | 154 M | 98.4 M | 85.1 M | 55.7 M | 38.4 M | - | - | - | - | - | - |
Cost of Revenue |
71.4 M | 72.1 M | 75.6 M | 57.9 M | 49.3 M | 22.5 M | 22.3 M | 19.7 M | 15.7 M | - | - | - | - | - | - |
Gross Profit |
206 M | 107 M | 94.7 M | 127 M | 105 M | 75.9 M | 62.8 M | 36 M | 22.8 M | - | - | - | - | - | - |
Operating Income |
-57.1 M | -163 M | -227 M | -200 M | -209 M | -153 M | -78.4 M | -49.8 M | -44.5 M | - | - | - | - | - | - |
Interest Expense |
11.8 M | 11.6 M | 13.8 M | 4.24 M | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-41.1 M | -145 M | -207 M | -179 M | -197 M | -146 M | -76.7 M | -48.1 M | -41.9 M | - | - | - | - | - | - |
Operating Expenses |
263 M | 269 M | 322 M | 328 M | 314 M | 229 M | 141 M | 85.8 M | 66.4 M | - | - | - | - | - | - |
General and Administrative Expenses |
72.7 M | 72.8 M | 83.9 M | 88.5 M | 74.5 M | 49.5 M | 30.3 M | 20.4 M | 15.9 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Adaptive Biotechnologies Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
160 M | 160 M | 156 M | 474 K | 152 M | 152 M | 149 M | 193 M | 148 M | 147 M | 146 M | 174 M | 145 M | 144 M | 144 M | 182 M | 143 M | 142 M | 142 M | 295 K | 141 M | 140 M | 139 M | 1.93 M | 134 M | 127 M | 126 M | 18.6 M | 124 M | 13.3 M | 12.9 M | 12.8 M | 12.6 M | 12.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
2.81 M | -39.9 M | -20 M | -13.6 M | 9.54 M | -25.6 M | -29.8 M | -33.7 M | -32.1 M | -46.2 M | -47.5 M | -69.5 M | -50.3 M | -47.8 M | -57.7 M | -40.2 M | -45.3 M | -52.1 M | -62.8 M | -54.6 M | -56 M | -56 M | -40.6 M | -44.6 M | -36.7 M | -33.5 M | -31.4 M | -20.6 M | -14 M | -16.4 M | -18.4 M | - | -8.29 M | -12.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
83.9 M | 71.6 M | 70.9 M | 71.7 M | 94 M | 58.9 M | 52.4 M | 47.5 M | 46.4 M | 43.2 M | 41.9 M | 45.8 M | 37.9 M | 48.9 M | 37.6 M | 55.2 M | 47.8 M | 43.7 M | 38.6 M | 37.9 M | 39.5 M | 38.5 M | 38.4 M | 30.2 M | 26.3 M | 21 M | 20.9 M | 24.2 M | 26.1 M | 22.1 M | 12.7 M | - | 17.2 M | 11.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
19.9 M | 20.2 M | 18.7 M | 18.2 M | 18.2 M | 18 M | 17 M | 18 M | 16.7 M | 19.3 M | 18.1 M | 19.6 M | 19.3 M | 17.9 M | 18.7 M | 16.6 M | 14.9 M | 13.2 M | 13.2 M | 14.4 M | 14.2 M | 10.8 M | 9.99 M | 6.22 M | 6.05 M | 4.91 M | 5.34 M | 5.95 M | 5.6 M | 5.73 M | 4.99 M | - | 5.36 M | 5.04 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
64 M | 51.4 M | 52.2 M | 53.5 M | 75.8 M | 40.9 M | 35.5 M | 29.4 M | 29.8 M | 23.9 M | 23.8 M | 26.2 M | 18.6 M | 31 M | 19 M | 38.6 M | 32.9 M | 30.4 M | 25.4 M | 23.6 M | 25.3 M | 27.7 M | 28.5 M | 24 M | 20.2 M | 16.1 M | 15.6 M | 18.3 M | 20.5 M | 16.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-457 K | -15.8 M | -19.2 M | -12.8 M | 10.3 M | -25 M | -29.6 M | -33.8 M | -32.6 M | -47.3 M | -48.8 M | -71.1 M | -51 M | -47.8 M | -57.2 M | -39.2 M | -45.4 M | -52.5 M | -63.1 M | -61.6 M | -56.3 M | -49.8 M | -41.3 M | -44.2 M | -37 M | -36.9 M | -34.6 M | -24.2 M | -18.1 M | -16.1 M | -20 M | - | -9.16 M | -13.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
503 K | 2.69 M | 2.89 M | 2.95 M | 2.97 M | 2.95 M | 2.9 M | 2.95 M | 2.94 M | 2.7 M | 2.99 M | 3.01 M | 3.65 M | 3.6 M | 3.53 M | 3.58 M | 653 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-29 K | -15.3 M | -18.8 M | -12.3 M | 10.7 M | -24.6 M | -29.2 M | -33.4 M | -32.2 M | -46.9 M | -48.3 M | -70.6 M | -50.5 M | -47.4 M | -56.8 M | -38.8 M | -45 M | -52.1 M | -62.6 M | -61.2 M | -55.9 M | -49.3 M | -40.9 M | -43.8 M | -36.6 M | -36.5 M | -34.2 M | -23.8 M | -17.6 M | -15.7 M | -18.7 M | - | -6.02 M | -11.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
64.4 M | 67.2 M | 71.4 M | 66.2 M | 65.5 M | 65.9 M | 65.1 M | 63.3 M | 62.4 M | 71.2 M | 72.6 M | 97.2 M | 69.5 M | 78.8 M | 76.2 M | 77.8 M | 78.4 M | 82.9 M | 88.5 M | 85.2 M | 81.6 M | 77.5 M | 69.7 M | 68.2 M | 57.3 M | 53 M | 50.2 M | 42.4 M | 38.5 M | 32.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
18.5 M | 21.2 M | 21 M | 19.6 M | 18 M | 17.8 M | 17.4 M | 18.1 M | 17.3 M | 17.9 M | 19.6 M | 20.7 M | 20.1 M | 22.3 M | 20.8 M | 22.4 M | 20.8 M | 21.2 M | 24.1 M | 23.3 M | 20.2 M | 16.1 M | 14.9 M | 13.4 M | 12.1 M | 12.2 M | 11.8 M | 8.19 M | 8.48 M | 6.66 M | 7 M | - | 4.74 M | 4.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Adaptive Biotechnologies Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
